Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Verdinexor (Primary)
- Indications Post-transplant lymphoproliferative disorder; Systemic lupus erythematosus; Viral infections
- Focus Adverse reactions
- Sponsors Karyopharm Therapeutics
- 18 Mar 2021 Time frame of primary endpoint representing adverse reactions changed from 46 to 33 weeks. Study design changed from parallel to sequential.
- 18 Mar 2021 Status changed to discontinued.
- 21 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.